GSK to mark launching ceremony of adefovir dipivoxil for treatment of chronic hepatitis B

Published: 2004-02-10 06:58:00

Updated: 2004-02-10 06:58:00

GSK announced recently that following the launching of Zeffix (lamivudine), it will hold an international launching symposium for adefovir dipivoxil in February 14. The drug is a nucleotide analogue that demonstrated clinically significant antiviral activity in patients with chronic hepatitis B in phase 1 and 2 clinical trials.

A senior official from GSK said that a total of 500 specialists,...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.